BFM
PTX

Boothbay Fund Management’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Boothbay Fund Management’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,330
Closed -$25K – 999
2017
Q4 		$25K Buy
+10,330
New +$28.6K ﹤0.01% 683
2015
Q2 		– Sell
-1,806
Closed -$193K – 536
2015
Q1 		$193K Buy
+1,806
New +$172K 0.13% 248

Other funds holding PTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Boothbay Fund Management's PTX Position: Q1 2018 in Review

Boothbay Fund Management sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q1 2018, closing a stake of 10,330 shares — an estimated $25K sold.

Boothbay Fund Management first reported a position in PTX in Q1 2015 and held it in 2 quarters. The position peaked at $193K in Q1 2015. 33 funds tracked by Wall St. Rank hold PTX as of Q1 2018.

  • Boothbay Fund Management reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q1 2018 after selling out during the quarter.
  • Boothbay Fund Management sold 10,330 Pernix Therapeutics Holdings, Inc. shares in Q1 2018, an estimated $25K.
  • Boothbay Fund Management first reported a position in Pernix Therapeutics Holdings, Inc. in Q1 2015 and held it in 2 quarters.
  • Boothbay Fund Management's Pernix Therapeutics Holdings, Inc. position peaked at $193K in Q1 2015.
  • 33 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q1 2018.

Based on Boothbay Fund Management's 13F filing for Q1 2018, filed 14 May 2018.